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Abstract
The prevalence of obesity and diabetes is increasing 
rapidly. Coronary artery disease (CAD) represents the 
leading cause of death in diabetic patients. Diabetic 
patients are at a two- to fourfold risk of cardiovascular 
mortality compared with their nondiabetic counter-
parts. Silent myocardial ischemia more often occurs in 
diabetics than in nondiabetics. In general, the preva-
lence of silent CAD varies depending on the test used 
for patient screening and on the patient population 
screened. The prevalence of silent CAD is 6–23% in 
low-risk diabetic patients. In high-risk diabetic patients 
the prevalence may be as high as 60%. Over the last 
years it has been well recognized that silent CAD is not 
different from symptomatic CAD with respect to prog-
nosis and adverse events. Particular diabetic patients 
therefore might benefit from routine CAD screening. 
CAD could be diagnosed at an earlier stage of disease 
and be treated accordingly. Myocardial perfusion 
SPECT, stress echocardiography and possibly computed 
tomography are emerging as effective screening tools 
beyond risk stratification by risk factor scoring systems 
alone. There are few studies suggesting that early in-
tervention by medical or also revascularization strate-
gies could lead to a better outcome in diabetic patients 
with evidence of silent CAD.
Prognostische Bedeutung der stummen KHK beim Typ-2-Diabetes
Zusammenfassung
Adipositas und Diabetes nehmen in ihrer Häufigkeit 
rasch zu. Eng damit verbunden ist eine sich entwickeln-
de „Epidemie“ der koronaren Herzkrankheit (KHK). 
Diabetiker haben eine zwei- bis vierfach höhere kardi-
ovaskuläre Mortalität als Nichtdiabetiker. Zudem ver-
läuft die KHK bei Diabetikern nicht selten stumm. Das 
Symptom der Angina pectoris stellt lediglich die Spitze 
des Eisberges der ischämischen Kaskade dar (Abbil-
dung 1). Die Prävalenz der stummen KHK hängt vom 
verwendeten Screeningtest und von der untersuchten 
Patientenpopulation ab. Bei Diabetikern mit niedrigem 
Risiko liegt die Prävalenz der stummen KHK bei 6–23%. 
Bei diabetischen Patienten mit höherem Risiko (Pati-
enten mit Endorganschäden wie peripherer arterieller 
Verschlusskrankheit, Mikroalbuminurie, Retinopathie, 
autonomer kardialer Neuropathie) ist sie deutlich hö-
her. Je nach Studie leiden bis 60% dieser Patienten an 
einer stummen KHK. Mögliche Ursachen für das Vorlie-
gen einer stummen KHK sind in Tabelle 1 aufgeführt. 
Für die Untersuchung von Patienten mit stummer 
Ischämie stehen uns heute mehrere effektive bild-
gebende Verfahren zur Verfügung (myokardiale Perfu-
sions-szintigraphie [MPS] in Ruhe und bei Belastung, 
Stressechokardiographie, Stressmagnetresonanztomo-
graphie und möglicherweise auch die hochauflösende 
Computertomographie zur nichtinvasiven CT-Angio-
graphie). Für die MPS gibt es gegenwärtig noch die 
besten Daten bezüglich Prävalenz und Pro gnose der 
stummen KHK. Diabetische Patienten mit einem nor-
malen MPS haben eine verhältnismäßig gute Progno-
se, wenn auch die jährliche kardiovaskuläre Ereignis-
rate nicht < 1% liegt, wie dies für Nichtdiabetiker mehr-
fach an großen Patientengruppen gezeigt werden 
konnte (Abbildungen 2 und 3). Die Hinweise mehren 
sich, dass nicht so sehr die Symptomatik der Diabetiker, 
sondern vielmehr die objektive Evidenz einer KHK für 
die Prognose entscheidend ist. Dementsprechend soll-
ten alle Diabetiker mit hohem Risiko, aber auch atypi-
schen Beschwerden hinsichtlich einer KHK untersucht 
werden. Liegen Hinweise für eine stumme KHK vor, le-
gen die ersten Studienergebnisse nahe, dass auch die 
Therapie von asymptomatischen Diabetikern deren 
Prognose verbessern kann. Zudem ist im Alltag zu be-
achten, dass auch ein normaler Ischämiesuchtest le-
diglich eine Momentaufnahme darstellt und je nach 
Patientenrisiko nach einem gewissen Zeitintervall wie-
derholt werden sollte („Garantiedauer“ eines norma-
len Tests).
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Introduction
The prevalence of obesity and diabetes is increasing rap-
idly which is due to human behavior and lifestyle chang-
es. Sedentary lifestyle, rich nutrition and obesity are 
precursors of diabetic development. Worldwide, there 
will be an increase of diabetes incidence from 151 mil-
lion patients in the year 2000 to 221 million patients in 
the year 2010 which is consistent with an increase of 
46% [1]. Furthermore, there are several studies suggest-
ing that diabetic patients without prior coronary artery 
disease (CAD) have as high a risk of myocardial infarc-
tion as nondiabetic patients with prior myocardial in-
farction [2]. An autopsy study demonstrated that among 
diabetic decedents without clinical CAD, almost 75% of 
patients had high-grade coronary atherosclerosis and > 
50% had multivessel disease. In the absence of diabetes, 
women had less coronary atherosclerosis than did men, 
but this female advantage was lost with diabetes [3]. In 
addition, CAD represents the leading cause of death in 
patients with diabetes [4]. Atherosclerosis accounts for 
65–80% of all deaths among diabetic patients, compared 
with one third of all deaths in the general population [5]. 
The cardiovascular mortality rate is more than twice as 
high in diabetic men and more than fourfold greater in 
diabetic women, compared with their nondiabetic coun-
terparts [6]. These facts add to the prospect that an “epi-
demic” of CAD  will emerge over the coming decades.
Since diabetics often present with silent CAD, 
they lack an important clinical “warning symptom” of 
their CAD.
The aim of this review therefore is fourfold: (1) to 
discuss the definition and the potential mechanisms 
of silent CAD in diabetic patients; (2) to summarize 
published data dealing with the prevalence of silent 
CAD; (3) to look at the prognostic significance of si-
lent CAD in diabetes; (4) to elucidate first therapeu-
tic approaches in silent CAD.
Definition and Potential Mechanisms 
of Silent CAD
Silent CAD is a term generally used to describe CAD or 
myocardial ischemia in the absence of chest pain or an-
gina but in the presence of objective evidence of myo-
cardial ischemia or CAD. Chest pain and angina repre-
sent only the “tip of the iceberg” in the ischemic cascade 
(Figure 1). There is a close interaction of coronary ste-
nosis, decreased myocardial perfusion, and impaired 
myocardial function before patients notice chest pain. 
Nowadays, cardiac examination techniques provide 
possibilities to monitor the ischemic cascade at its sev-
eral steps. The gold standard to visualize coronary ar-
tery stenosis still is coronary angiography. Even though, 
computed tomography (CT) is a rapidly developing and 
emerging tool for the assessment of ischemic heart dis-
ease, including visualization of the coronary arteries. 
Noninvasive coronary imaging still poses the greatest 
challenge to any diagnostic technique. This is due to the 
fact that the coronary arteries are small, tortuous, and 
course in multiple planes around the heart, whereas car-
diac contraction and respiration cause motion artifacts. 
There are several tools to monitor myocardial perfu-
sion. The most robust and standardized method is still 
myocardial perfusion SPECT (MPS) and positron emis-
sion tomography (PET) although magnetic resonance 
(CMR) has huge potential to emerge as an effective im-
aging technique in the assessment of CAD. For stress 
echocardiography similar sensitivities and specificities 
may be expected as for MPS, if there is a good acoustic 
window; however, “diabetic cardiomyopathy” may limit 
this test to identify CAD in diabetics. Currently, out-
come data in diabetic patients following stress echocar-
diography is still too limited to define its role as a prog-
nostic tool in these patients.
The advantage of cardiac imaging techniques 
when compared to stress testing without imaging is 
the possibility to gather a lot of additional informa-
tion, e.g., the extent and amount of ischemia and left 
ventricular ejection fraction.
The reasons for silent CAD in diabetes are plenty 
[7–10]. Table 1 summarizes the mostly discussed 
mechanisms.
Prevalence of Silent CAD
In general, the prevalence of silent myocardial isch-
emia varies depending on the patient population 
screened and the test used for patient evaluation. In 
patients without known prior CAD, the prevalence of 
silent CAD is 2.5–11% in nondiabetic patients as com-
pared to 6.4–23% in low-risk diabetic patients [11–15]. 
No ischemia
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Figure 1. Ischemic cascade. Cath: coronary angiography; CMR: cardiac magnetic 
resonance; CT: computed tomography; Echo: echocardiography; MPS: myocardial 
perfusion SPECT; PET: positron emission tomography.
Abbildung 1. Ischämische Kaskade. Cath: Herzkatheter; CMR: Magnetresonanzto-
mographie des Herzens; CT: Computertomographie; Echo: Echokardiographie; MPS: 
myokardiale Perfusionsszintigraphie; PET: Positronenemissionstomographie.
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To date, there is only one study that has prospectively 
evaluated the prevalence of silent CAD in diabetic pa-
tients. Wackers et al. conducted the Detection of silent 
myocardial Ischemia in Asymptomatic Diabetic sub-
jects (DIAD) study [16]. 522 patients were screened by 
MPS. Of these, 22% had an abnormal stress test result. 
Cardiac autonomic neuropathy turned out to be the 
only independent predictor of abnormal MPS – none 
of the well-known CAD risk factors.
There are groups of diabetic patients that are at 
particularly high risk of silent CAD. These groups are 
in part defined by other diabetic end-organ damages: 
peripheral arterial disease, cerebrovascular disease, 
nephropathy (microalbuminuria), retinopathy, and 
autonomic cardiac neuropathy.
Nesto et al. assessed the prevalence of silent CAD 
in a small population of patients with known peripheral 
vascular disease (n = 30) [17]. 17 patients (57%) had 
thallium abnormalities, with reversible thallium de-
fects compatible with ischemia in 14 patients (47%) 
and evidence of prior, clinically silent myocardial in-
farction in eleven patients (37%). With respect to ne-
phropathy, Rutter et al. described a significant differ-
ence in positive exercise treadmill tests of diabetic pa-
tients with microalbuminuria (65%) versus patients 
without microalbuminuria (40%; p = 0.013) [18]. A 
pooled analysis revealed that the prevalence of silent 
CAD was 28% and 10%, in patients with and without 
autonomic cardiac neuropathy, respectively [19]. How-
ever, it is difficult to find data regarding the relation of 
retinopathy, cerebrovascular disease and silent CAD.
Prognosis of Silent CAD in Diabetic Patients
The relatively high prevalence of silent CAD in particu-
lar diabetic patient populations stresses the fact that 
prognostic considerations of this problem are crucial.
There is limited data about the prognosis of dia-
betic patients with silent CAD. In general, it has been 
shown that the cardiovascular mortality rate is more 
than doubled in diabetic men and raised more than 
fourfold in diabetic women, when compared with 
their nondiabetic counterparts [6, 20]. In addition, 
diabetic patients are less likely to survive a first myo-
cardial infarction than nondiabetic patients [21].
In a large patient population (n = 1,437), Weiner 
et al. demonstrated that when myocardial ischemia 
(whether silent or symptomatic) was present during 
exercise testing, the long-term survival among diabet-
ics was worse than that of nondiabetics [22]. By con-
trast, when ischemia was absent, there was no higher 
mortality risk for diabetic patients. Importantly, sur-
vival rates among patients with silent ischemia were 
similar to those of symptomatic patients regardless of 
diabetic status. These findings are consistent with an-
other survival analysis by Pancholy et al. [23] that 
demonstrated no significant difference in the 
event-free survival in 521 patients with symptomatic 
or silent ischemia over the time period of 2 years. The 
extent of perfusion abnormality and history of diabe-
tes were the most important predictors of events.
Rajagopalan et al. examined angiographic find-
ings and mortality rates in 826 asymptomatic diabetic 
patients with respect to MPS findings [24, 25]. The 
mortality rate in high-risk patients was 5.9%, in inter-
mediate-risk patients 5.0%, and in low-risk patients 
3.6% (p < 0.001 for differences between groups). Post 
hoc analyses were performed to determine if a truly 
low-risk (annual mortality < 1%) subset of patients 
could be identified. Annual mortality in patients with-
out ECG Q-waves or peripheral arterial disease and 
with a completely normal SPECT imaging scan (n = 
443) was lower but was still 2.9%. The annual mortal-
ity rate was higher in patients with preoperative ver-
sus other indication for MPS evaluation (5.9% vs. 
2.7%; p < 0.001). The annual mortality rate for pa-
tients without preoperative indication whose scan 
was normal (n = 298) amounted to 1.9%. For patients 
without preoperative indication, Q-waves, or periph-
eral arterial disease, the annual mortality rate was 
1.6% for those with a normal scan (n = 237) and 3.4% 
for those with a high-risk scan (n = 79). Importantly, 
although a normal MPS study is generally associated 
with a low risk (< 1% annual risk of cardiac death or 
myocardial infarction), the challenge in a diabetic 
population is to define the elusive “low-risk” patient. 
To date, reports have consistently shown that normal 
MPS in diabetic populations is not associated with 
this low level of risk and, in direct comparisons, pa-
tients with diabetes are at significantly greater risk 
than nondiabetics with normal MPS [24, 26–29]. Simi-
larly, in the setting of an abnormal MPS, the risk con-
ferred by any given extent and severity of perfusion 
Table 1. Reasons for silent coronary artery disease/isch-
emia.
Table 1. Gründe für die stumme koronare Herzkrankheit/
Ischämie.
• Lesser severity and duration of ischemia
• Prior Q-wave myocardial infarction
• Diabetes mellitus
• Autonomic cardiac dysfunction
• Coronary collateral flowa
•  Psychological characteristics, such as decreased awareness of 
somatic pain and other body sensations
• Lower depression scores
•  Enhanced secretion of endogenous opiates may minimize 
perception of pain
a collateral flow may be so marked, that myocardial perfusion becomes 
normal
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abnormality is greater in patients with diabetes than 
in nondiabetics.
We assessed the incidence of MPS evidence of 
CAD in diabetic patients without known CAD and 
the impact of symptoms and scintigraphic findings on 
prognosis [26]. Objective evidence of CAD was found 
in 39% of 826 asymptomatic diabetic patients, in 51% 
of 151 diabetic patients with shortness of breath 
(SOB), and in 44% of 760 diabetic patients with an-
gina. Overall, patients with a normal MPS had quite a 
good prognosis irrespective of symptomatic status, 
even though it was not < 1%. Patients with an abnor-
mal MPS had a significantly worse outcome. Of note, 
there was no prognostic difference in patients with 
abnormal MPS when asymptomatic patients and pa-
tients with angina were compared (Figures 2 and 3). 
By contrast, patients with SOB had a very high event 
rate, reflecting in part that these patients had more 
often suffered a silent myocardial infarction than 
asymptomatic patients and patients with angina. In 
the multivariate Cox proportional hazards model, 
age, hypertension, SOB, extent of scarring, and ex-
tent of ischemia were independent predictors of 
events. Hypercholesterolemia and family history of 
CAD tended to be independent predictors of events. 
Of note, angina was not a significant predictor of crit-
ical events in this model, but SOB was. MPS added 
incremental information to clinical and prescan infor-
mation to predict outcome, indicating that MPS seems 
to be valuable for risk stratification of asymptomatic 
diabetic patients with respect to the diagnosis of CAD 
and its prognosis.
An even more difficult question is the “warranty 
period” of a normal MPS regarding prognosis. There 
is data suggesting that it is only around 1 year in dia-
betic patients [30].
Calcium scoring and coronary angiography by 
computed tomography has emerged as a screening 
tool for CAD. Schurgin et al. evaluated 139 diabetic 
patients with respect to the calcium score as assessed 
by computed tomography [31]. Diabetic patients were 
then compared to a randomly selected nondiabetic 
patient group. Patients with diabetes had a signifi-
cantly higher prevalence of calcium scores > 400 
(25.9%) compared with the randomly selected (7.2%) 
and matched (14.4%) nondiabetic control group. 
Scores above the range of 400 have been reported to 
be highly predictive of abnormal MPS and subsequent 
coronary events. Raggi et al. evaluated the prognostic 
value of calcium score measurements in diabetic pa-
tients [32]. Mortality from all causes was increased in 
asymptomatic patients with diabetes in proportion to 
the screening calcium score. Nonetheless, subjects 
without coronary artery calcium had a low short-term 
risk of death even in the presence of diabetes mellitus. 
Moreover, the presence of any degree of coronary ar-
tery calcium in patients with diabetes mellitus por-
tended a higher risk for all-cause mortality than in 
nondiabetic patients.
Patients with autonomic cardiac neuropathy have 
a higher incidence of silent myocardial ischemia than 
patients without autonomic cardiac neuropathy [19, 
33, 34]. Furthermore, the former have a significantly 
higher mortality rate than the latter, 30% and 13%, 
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Figure 2. Annual hard event rates (cardiac death or nonfatal myocardial infarction) 
as a function of symptoms and MPS (myocardial perfusion SPECT) findings (n = 
1,430; adapted from [26]). SOB: shortness of breath.
Abbildung 2. Jährliche Ereignisraten (kardialer Tod oder nichtfataler Myokardin-
farkt) als Funktion der Symptomatik und der MPS-Resultate (n = 1 430; modifiziert 
nach [26]). SOB: Dyspnoe. 
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Figure 3. Kaplan-Meier survival curves in patients with abnormal MPS (n = 509; 
adapted from [26]). SOB: shortness of breath.
Abbildung 3. Kaplan-Meier-Überlebenskurven bei Patienten mit abnormem MPS 
(n = 509; modifiziert nach [26]).  SOB: Dyspnoe.
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respectively [19, 33, 34]. It seems that evaluation of 
cardiac autonomic neuropathy might help to identify 
diabetic patients at particularly high risk.
Clinical Implications
The epidemic of diabetes has left us with the chal-
lenge of identifying those asymptomatic individuals 
with diabetes who have silent or occult CAD. Data is 
supporting the fact that not symptoms play the impor-
tant role for patient prognosis but objective evidence 
of CAD. It is also crucial to bear in mind that diabetic 
patients can present with atypical symptoms of CAD 
(e.g., with symptoms of easy fatigability, exertional 
SOB, or indigestion).
An individual assessment of cardiac risk is impor-
tant to decide if a diabetic patient should be tested and 
also when the patient should be reevaluated (warranty 
period of a normal test) which has plenty of implications 
(e.g., patient safety, radiation exposure, costs). Gener-
ally, it appears that clinical information adds incremen-
tal prognostic value over perfusion results and can fur-
ther risk-stratify MPS results. These factors include pa-
tient gender, age, presence of peripheral vascular 
disease, microalbuminuria, retinopathy, autonomic 
neuropathy, or abnormal resting ECG. The consensus 
paper of the American Diabetes Association provides 
useful information regarding diagnostic strategies in di-
abetic patients [35]. Even though, these recommenda-
tions were based on the clinical judgment of a panel of 
experts rather than on published data [36].
The question of therapeutic approaches in silent 
CAD is an important question of ongoing debate. 
The data dealing with this issue is scarce. There is 
only one pilot study in a general population that has 
prospectively addressed different therapeutic ap-
proaches in silent CAD: the Asymptomatic Cardiac 
Ischemia Pilot (ACIP) study [37]. The study demon-
strated that a strategy of initial revascularization ap-
peared to improve the prognosis of a general popula-
tion with silent CAD compared with angina-guided 
medical therapy [37]. In addition, recent data from 
the Mayo Clinic provide some evidence regarding the 
value of MPS in relation to outcome in diabetic pa-
tients [38]. They evaluated 826 asymptomatic diabetic 
patients without prior CAD and abnormal MPS. Re-
vascularization was performed in 21% of patients 
with high-risk MPS. Revascularization revealed to be 
an independent predictor of improved survival in 
these patients.
It might also be that rigorous primary and sec-
ondary prevention by statins will lead to stabilization 
and regression of CAD in diabetic patients. There are 
several studies demonstrating that there was a signifi-
cant decrease of coronary calcium scores in patients 
effectively treated by statins [38, 39].
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